CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 1 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $201,000 | -60.5% | 40,300 | 0.0% | 0.00% | – |
| Q4 2020 | $509,000 | +28.5% | 40,300 | 0.0% | 0.00% | – |
| Q3 2020 | $396,000 | -1.2% | 40,300 | 0.0% | 0.00% | – |
| Q2 2020 | $401,000 | +26.1% | 40,300 | +11.9% | 0.00% | – |
| Q1 2020 | $318,000 | -4.2% | 36,000 | 0.0% | 0.00% | – |
| Q4 2019 | $332,000 | +56.6% | 36,000 | 0.0% | 0.00% | – |
| Q3 2019 | $212,000 | -50.9% | 36,000 | 0.0% | 0.00% | – |
| Q2 2019 | $432,000 | +30.9% | 36,000 | +31.9% | 0.00% | – |
| Q1 2019 | $330,000 | +3.4% | 27,300 | +7.5% | 0.00% | – |
| Q4 2018 | $319,000 | -7.8% | 25,400 | +9.0% | 0.00% | – |
| Q3 2018 | $346,000 | -7.0% | 23,300 | +5.4% | 0.00% | – |
| Q2 2018 | $372,000 | -8.1% | 22,100 | +24.9% | 0.00% | – |
| Q1 2018 | $405,000 | +13.4% | 17,700 | +28.3% | 0.00% | – |
| Q4 2017 | $357,000 | +94.0% | 13,800 | +10.4% | 0.00% | – |
| Q3 2017 | $184,000 | +5.7% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $174,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,200,000 | $37,532,000 | 7.45% |
| BVF INC/IL | 2,336,609 | $39,863,000 | 6.78% |
| ISZO CAPITAL MANAGEMENT LP | 152,988 | $2,610,000 | 4.54% |
| SENZAR ASSET MANAGEMENT, LLC | 416,845 | $7,111,000 | 1.80% |
| INGALLS & SNYDER LLC | 1,056,000 | $18,015,000 | 0.96% |
| Lyon Street Capital, LLC | 86,011 | $1,467,000 | 0.59% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 430,982 | $7,353,000 | 0.25% |
| AWM Investment Company, Inc. | 137,212 | $2,340,000 | 0.22% |
| ACUTA CAPITAL PARTNERS, LLC | 49,051 | $837,000 | 0.20% |
| Schonfeld Strategic Advisors LLC | 61,831 | $1,055,000 | 0.11% |